ArticleBMC urology2024

RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.

Jiajun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.